Anula Jayasuriya, MD, PhD, MBA is a life science venture capitalist. Anula is the co-founder of the "Evolvence India Life Science Fund" (EILSF), established in 2006 to make investments in pharmaceutical, biotechnology, medical device and related contract service companies based in India. The fund has had an initial closing of US $50 million and made its first investment. She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German - US venture capital firm TVM, in San Francisco. Anula's expertise consists of a unique combination of business, basic science and medical knowledge. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children's Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, England.